Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 4,800 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 4,800 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $4.38, for a total transaction of $21,024.00. Following the sale, the chief executive officer now owns 14,591,736 shares in the company, valued at $63,911,803.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Stock Down 1.7 %

Shares of NASDAQ VRNA opened at $33.86 on Friday. The company has a current ratio of 8.61, a quick ratio of 8.61 and a debt-to-equity ratio of 0.72. The firm has a fifty day simple moving average of $29.96 and a two-hundred day simple moving average of $21.47. The firm has a market capitalization of $2.71 billion, a PE ratio of -43.97 and a beta of 0.44. Verona Pharma plc has a 12 month low of $11.39 and a 12 month high of $35.62.

Verona Pharma (NASDAQ:VRNA) last posted its earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same period last year, the company earned ($0.11) EPS. Equities analysts expect that Verona Pharma plc will post -2.07 earnings per share for the current year.

Analysts Set New Price Targets

VRNA has been the topic of several analyst reports. Wells Fargo & Company initiated coverage on shares of Verona Pharma in a report on Thursday, October 3rd. They set an “overweight” rating and a $50.00 price target on the stock. Canaccord Genuity Group boosted their price target on shares of Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. Truist Financial upped their target price on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of Verona Pharma in a report on Tuesday, October 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $39.33.

Institutional Trading of Verona Pharma

Several hedge funds have recently bought and sold shares of VRNA. CWM LLC bought a new position in Verona Pharma during the 2nd quarter valued at about $29,000. EMC Capital Management purchased a new position in shares of Verona Pharma in the second quarter worth $38,000. GAMMA Investing LLC raised its holdings in shares of Verona Pharma by 70.6% in the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock worth $38,000 after buying an additional 553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Verona Pharma by 25.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after acquiring an additional 529 shares during the period. Finally, Legato Capital Management LLC acquired a new stake in shares of Verona Pharma in the second quarter worth $154,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.